I hope this helps to explain clinical trail phases. They would not change the compound itself, but dosage would/could be modified. All phases are obviously important in proving the efficacy of a new medication, but on average, 70% of Phase I meds move on to Phase II. Once Phase II is complete, the percentage drops to 33% of meds moving on to Phase III, so PII is pretty darn vital. These are just averages across every med that has passed through the FDA, so take them as a guideline, and not specific to Aut063. Also keep in mind that there are vast numbers of meds that don't even reach Phase I let alone PII, so Aut063 is on a positive path.
- Phase I: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
- Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
- Phase III: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
- Phase IV: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.